Naoki Inui1, Noboru Yamamoto2, John V.Heymach3, Jon Zugazagoitia4, Yi-Long Wu5, Gerrina Ruiter6,7, Motohiro Tamiya8, Shunichi Sugawara9, Myung-Ju Ahn10, Nicolas Girard11,12, Behbood Sadrolhefazi13, Maren Rohrbacher14, Jianrui Hou15, Sabina Eigenbrod-Giese14, Kiyotaka Yoh16
1Department of Clinical Pharmacology and Therapeutics, Division of Respiratory Medicine, Hamamatsu University School of Medicine, 2Department of Experimental Therapeutics, National Cancer Center Hospital, 3Department of Thoracic / Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, 4Department of Medical Oncology, 12 de Octubre Hospital, 5Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 6Department of Clinical Pharmacology, Netherlands Cancer Institute, 7Department of Thoracic Oncology, Netherlands Cancer Institute, 8Department of Thoracic Oncology, Osaka International Cancer Institute, 9Department of Pulmonary Medicine, Sendai Kousei Hospital, 10Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 11Institut Curie, Institut du Thorax Curie-Montsouris, 12Paris Saclay University, UVSQ, 13Boehringer Ingelheim Pharmaceuticals, Inc., 14Boehringer Ingelheim International GmbH, 15Nippon Boehringer Ingelheim Co., Ltd., 16Department of Thoracic Oncology, National Cancer Center Hospital East
Japanese Journal of Lung Cancer 65(5): 420-421, 2025.